{
  "specialty": "Hepatology",
  "condition": "oncology_chemotherapy_immunotherapy_hepatotoxicity",
  "template_name": "hepatology_oncology_chemotherapy_immunotherapy_hepatotoxicity",
  "sections": [
    {
      "My Clinical Question (condition: chemotherapy/immunotherapy hepatotoxicity)": "***"
    },
    {
      "My most current assessment of this problem can be found in the note dated": "{Today/***}"
    },
    {
      "In your clinical question, or current note, please include information on": {
        "Assessments": [
          {
            "Disease being treated and (suspected) offending agent": "***"
          },
          {
            "Was the offending agent stopped": "***"
          },
          {
            "Any preexisting (pretreatment) hepatic disease": "***"
          },
          {
            "HBV (pretreatment) screening results": [
              {
                "Hepatitis B surface antigen (HbSAg)": "***"
              },
              {
                "Hepatitis B core antibody (anti-HBc)": "***"
              },
              {
                "Total immunoglobulin (Ig) or IgG": "***"
              },
              {
                "Antibody to hepatitis B surface antigen (anti-HBs)": "***"
              }
            ]
          }
        ],
        "Diagnostics": {
          "Required": [
            {
              "CMP (AST, ALT, Bilirubin, Alk Phos)": "***"
            },
            {
              "GTT": "***"
            }
          ],
          "Optional": [
            {
              "HAV Ab": "***"
            },
            {
              "HBsAg": "***"
            },
            {
              "Anti-HBc": "***"
            },
            {
              "Anti-HBs": "***"
            },
            {
              "HCV Ab": "***"
            },
            {
              "CMV": "***"
            },
            {
              "Abdominal ultrasound": "***"
            },
            {
              "Abdominal CT": "***"
            }
          ]
        },
        "Clinical Pearls": [
          {
            "Additional information on chemotherapy-induced liver injury is available from the LiverTox, a collaborative effort of the Liver Disease Research Branch of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine (NLM). LiverTox is a freely accessible website that provides continuously updated comprehensive and evidence-based information about the clinical features of liver injury from drugs, dietary supplements, and herbal products along with a complete and annotated list of references": "***"
          },
          {
            "Most hepatotoxic drug reactions are idiosyncratic and classified mechanistically either as immunologic (hypersensitivity) or metabolic": "***"
          },
          {
            "While the reaction to many chemotherapy drugs is manifested by hepatocellular injury, inflammation, and/or cholestasis, other agents cause endothelial damage or thrombosis leading to vascular complications such as hepatic veno-occlusive disease (VOD, also called hepatic sinusoidal obstruction syndrome [SOS])": "***"
          }
        ]
      }
    }
  ]
}